IL37 and inflammatory bowel disease: Given the central role of the IL-23 pathway in IBD, it may be speculated that a decrease in CD161 expression/IL-23 responsiveness with increasing age may partially explain the decreased disease incidence observed after the peak age of onset in childhood and early adulthood.